A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
Courtney WoolseyRobert W CrossKrystle N AgansViktoriya BorisevichDaniel J DeerJoan B GeisbertCheryl GerardiTheresa E LathamKarla A FentonMichael A EganJohn H EldridgeThomas W GeisbertDemetrius MatassovPublished in: PLoS neglected tropical diseases (2022)
These results emphasize the utility of Vesiculovax vaccines for MVD outbreak management. The highly attenuated nature of rVSV-N4CT1 vaccines, which are clinically safe in humans, may be preferable to vaccines based on the same platform as Ervebo (rVSV "delta G" platform), which in some trial participants induced vaccine-related adverse events in association with viral replication including arthralgia/arthritis, dermatitis, and cutaneous vasculitis.